Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
- PMID: 23814458
- PMCID: PMC3693864
- DOI: 10.2147/OPTH.S41750
Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
Abstract
Purpose: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the effect of bevacizumab as an adjunct to 5-FU on the intraocular pressure (IOP) outcome, bleb morphology, postoperative medications, and complications was evaluated.
Methods: Glaucoma patients (N = 61) who underwent trabeculectomy with mitomycin C were analyzed retrospectively (follow-up period of 25 ± 19 months). Surgery was performed exclusively by one experienced glaucoma specialist using a standardized technique. Patients in group 1 received subconjunctival applications of 5-FU postoperatively. Patients in group 2 received 5-FU and subconjunctival injection of bevacizumab.
Results: Group 1 had 6.4 ± 3.3 (0-15) (mean ± standard deviation and range, respectively) 5-FU injections. Group 2 had 4.0 ± 2.8 (0-12) (mean ± standard deviation and range, respectively) 5-FU injections. The added injection of bevacizumab significantly reduced the mean number of 5-FU injections by 2.4 ± 3.08 (P ≤ 0.005). There was no significantly lower IOP in group 2 when compared to group 1. A significant reduction in vascularization and in cork screw vessels could be found in both groups (P < 0.0001, 7 days to last 5-FU), yet there was no difference between the two groups at the last follow-up. Postoperative complications were significantly higher for both groups when more 5-FU injections were applied. (P = 0.008). No significant difference in best corrected visual acuity (P = 0.852) and visual field testing (P = 0.610) between preoperative to last follow-up could be found between the two groups.
Conclusion: The postoperative injection of bevacizumab reduced the number of subconjunctival 5-FU injections significantly by 2.4 injections. A significant difference in postoperative IOP reduction, bleb morphology, and postoperative medication was not detected.
Keywords: 5-fluorouracil; bevacizumab; bleb failure; bleb scarring; glaucoma; trabeculectomy.
Figures
Similar articles
-
Comparison of Efficacy and Safety of Bleb Needle Revision With and Without 5-Fluorouracil for Failing Trabeculectomy Bleb.J Glaucoma. 2019 May;28(5):386-391. doi: 10.1097/IJG.0000000000001226. J Glaucoma. 2019. PMID: 30839411
-
Assessing safety and success after using bevacizumab, 5-fluorouracil or placebo in primary trabeculectomy. A prospective randomized placebo controlled 1-year follow-up study.Cutan Ocul Toxicol. 2022 Mar;41(1):25-32. doi: 10.1080/15569527.2021.2003376. Epub 2022 Jan 25. Cutan Ocul Toxicol. 2022. PMID: 34749555 Clinical Trial.
-
Comparison of needle revision with subconjunctival bevacizumab and 5-fluorouracil injection of failed trabeculectomy blebs.J Ocul Pharmacol Ther. 2012 Oct;28(5):542-6. doi: 10.1089/jop.2012.0035. Epub 2012 Jun 25. J Ocul Pharmacol Ther. 2012. PMID: 22731246 Clinical Trial.
-
Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: a pilot study.Clin Exp Ophthalmol. 2012 Nov;40(8):773-9. doi: 10.1111/j.1442-9071.2012.02798.x. Epub 2012 Jun 4. Clin Exp Ophthalmol. 2012. PMID: 22429268 Clinical Trial.
-
Incidence and management of cataract after glaucoma surgery.Curr Opin Ophthalmol. 2013 Jan;24(1):15-20. doi: 10.1097/ICU.0b013e32835ab55f. Curr Opin Ophthalmol. 2013. PMID: 23222149 Review.
Cited by
-
LncRNA NR_003923 promotes cell proliferation, migration, fibrosis, and autophagy via the miR-760/miR-215-3p/IL22RA1 axis in human Tenon's capsule fibroblasts.Cell Death Dis. 2019 Aug 7;10(8):594. doi: 10.1038/s41419-019-1829-1. Cell Death Dis. 2019. PMID: 31391457 Free PMC article.
-
Use of 5-Fluorouracil-Soaked Bioamniotic Membranes in Trabeculectomy for Primary Open-Angle Glaucoma: A Retrospective Analysis.J Ophthalmol. 2017;2017:2698975. doi: 10.1155/2017/2698975. Epub 2017 Aug 6. J Ophthalmol. 2017. PMID: 28845303 Free PMC article.
-
Initial trabeculectomy with 5-fluorouracil with or without subconjunctival bevacizumab in the management of pseudoexfoliation glaucoma.Int Ophthalmol. 2019 Jun;39(6):1211-1217. doi: 10.1007/s10792-018-0926-y. Epub 2018 Apr 25. Int Ophthalmol. 2019. PMID: 29696466
-
Effect of purine-rich box1 on proliferation of fibroblasts.Int J Ophthalmol. 2020 Nov 18;13(11):1827-1832. doi: 10.18240/ijo.2020.11.22. eCollection 2020. Int J Ophthalmol. 2020. PMID: 33215017 Free PMC article. Review.
-
Improving patient outcomes following glaucoma surgery: state of the art and future perspectives.Clin Ophthalmol. 2014 May 2;8:857-67. doi: 10.2147/OPTH.S48745. eCollection 2014. Clin Ophthalmol. 2014. PMID: 24833892 Free PMC article. Review.
References
-
- O’Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol. 1991;111(4):491–500. - PubMed
-
- Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968;66(4):673–679. - PubMed
-
- Reddick R, Merritt JC, Ross G, Avery A, Peiffer RL. Myofibroblasts in filtration operations. Ann Ophthalmol. 1985;17(3):200–203. - PubMed
-
- Greenfield DS, Suñer IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW., Jr Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996;114(8):943–949. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources